Skip to main content
. 2022 Nov 29;13:1012981. doi: 10.3389/fimmu.2022.1012981

Figure 1.

Figure 1

CAR-T-38 therapy response in the two patients with CML-BP. (A) This part showed the bone marrow morphological feature of patients 1 and 2 before (up) and 2 weeks after CAR-T-38 treatment (upper lower). After CAR-T-38 cell infusion, the patient 1 (left, lower) and 2 (right, lower) achieved CR. (B) The blasts were gated by using a CD45, side scatter (SS), and CD34-based gating strategy, but CD34+ leukemia had lost CD34 expression as the disease progressed to BP in these two patients, and the blasts were gated according to CD45/SS gating strategy (left). The blast (A population, tomato red) rates of bone marrow mononuclear cells (blank, middle and right plots) were 28.8% and 7.3 × 10−4 before and 2 weeks after CAR-T-38 treatment, respectively. This CD34− AML blast fraction expressed CD38, CD117, CD33, CD13, CD123, and HLA-DR. (C) Both E255K and T315I mutation disappeared in bone marrow 2 weeks after CAR-T cell infusion. (D) Dynamic changes of BCR::ABL1 expression level (IS) of patient 1 in the course of the disease. Patient 1 was resistant to multiple TKIs [imatinib (IM), dasatinib (DAS), nilotinib (NIL), and ponatinib (PON)], intensive chemotherapy with idarubicin and cytarabine (IA), and interferon-α (IFN). The level of BCR::ABL1 was reduced to 0, 1 week after CAR-T treatment.